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Background/aim: We aimed to determine the presence of subclinical atherosclerosis using carotid intima-media thickness (CIMT) and
biochemical parameters in children and adolescents with congenital adrenal hyperplasia (CAH).
Materials and methods: Thirty-four patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency on
regular glucocorticoid treatment for ≥3 years and 31 healthy subjects were included in the study. The patients were divided into two
groups according to the degree of control of the clinic, laboratory, and radiological parameters as a) “uncontrolled” [n= 22; with increased
height velocity (HV) standard deviation score (SDS) (≥2 SDS), advanced bone age, serum 17-OH progesterone <2.0 and ≥10.0 ng/mL or
androstenedione <0.3 and ≥ 3.0 ng/mL] or b) “controlled” [n= 12; with HV SDS < 2, bone age (BA)/ chronologic age (CA) ratio < 1.2,
serum 17-OH progesterone between 2 and 10 ng/mL and androstenedione between 0.3 and 3.0 ng/mL]. Ultrasonographic examination
of carotid artery was performed by the same radiologist using a B-mode ultrasound system.
Results: There was no significant difference between the CAH and control groups in terms of median (IQR) CIMT values [0.47 (0.05)
mm and 0.47 (0.07) mm, respectively; p > 0.05]. When subgroup comparisons were done in terms of median (IQR) CIMT values, there
was no significant difference among the controlled, uncontrolled, and healthy control groups [0.45 (0.03) mm, 0.47 (0.04) mm, 0.47
(0.07) mm, respectively; p> 0.05]. In addition, CIMT levels were similar according to sex and disease control status.
Conclusion: In this study, the CIMT values of CAH cases were similar to those of healthy subjects.
Key words: Congenital adrenal hyperplasia, carotid intima-media thickness, subclinical atherosclerosis

1. Introduction
Congenital adrenal hyperplasia (CAH) is a group of
autosomal recessive disorders caused by mutations in
genes encoding the enzymes that are responsible for the
biosynthesis of cortisol. Deficiency of 21-hydroxylase
(21-OH) enzyme is the most common type of CAH,
accounting for >%95 of all CAH cases [1]. This type of
CAH is characterized by a decrease in the production
of cortisol and/or aldosterone and the accumulation of
precursor steroid hormones in the steroidogenic pathway
[2]. This disorder has a quite broad spectrum of clinic
form and is classified as classical type [salt-wasting (SW)
and simple virilizing (SV)] and mild nonclassic or lateonset CAH according to the degree of enzyme deficiency.
The SW type has the most severe phenotype and accounts
for 75% of the classic type. The SW type, usually with <2%

residual enzyme activity of 21-hydroxylase, is presented
by insufficient cortisol and aldosterone synthesis, and
excess androgen production. In SV type, unlike SW,
mineralocorticoid synthesis is sufficient. The nonclassic
type is characterized by an overproduction of androgens
only in adulthood [2,3]. The main goal in the treatment of
the disorder is to replace the hormones that are deficient
(cortisol and/or mineralocorticoid) and to suppress the
androgen hormones that are increased excessively [3].
For this purpose, in clinical practice, hydrocortisone and
fludrocortisone are frequently used for treatment.
Congenital adrenal hyperplasia due to 21-OH
deficiency is often associated with risk of obesity,
insulin resistance, hypertension, hyperandrogenism,
and dyslipidemia among children and adolescents [4,5].
Intermittent hypercortisolism associated with treatment
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and adrenomedullary dysfunction lead to these metabolic
disorders, resulting in an increased risk of developing
metabolic syndrome and atherosclerosis in CAH [6].
Although various organizations have different approaches
in defining metabolic syndrome, it is generally defined
as the presence of three of the following five criteria;
increased waist circumference, glucose intolerance, high
triglyceride, low high-density lipoprotein cholesterol, and
hypertension [7]. Metabolic syndrome components that
occur in this disease may cause endothelial dysfunction
and predispose patients to coronary artery disease and
stroke at an early age [6]. Carotid intima-media thickness
(CIMT) is a noninvasive test that is widely used to define
early subclinical atherosclerosis. Increased CIMT is a
parameter to predict increased risk of cardiovascular
events such as coronary artery disease and stroke [8].
Increased CIMT has previously been reported in children
with obesity, type 1 diabetes mellitus and hyperlipidemia
[9,10]. However, there are only a limited number of studies
evaluating CIMT in children and adolescents with CAH
[11–15].
The present study aimed to determine the presence of
subclinical atherosclerosis using CIMT and biochemical
parameters in children and adolescents with CAH.
2. Materials and methods
2.1. Subjects
This prospective study was conducted in 2014–2015, at
Dokuz Eylül University in İzmir. Thirty-four patients
with classic congenital adrenal hyperplasia due
to 21-hydroxylase deficiency and 31 healthy subjects
were included in the study. Age, pubertal status, and
sex-matched healthy controls were recruited from the
general pediatric outpatient clinic. Those with chronic
diseases were excluded from both CAH and the control
groups. The inclusion criteria for the CAH patients were
as follows i: having regular follow-up every 3 months
after diagnosis at our institution, ii: using hydrocortisone
± fludrocortisone treatment for at least 3 years. In this
study, which included classical type CAH cases, SW and
SV classification was determined according to clinical and
laboratory findings. Accordingly, patients who presented
with severe cases of salt wasting (vomiting, failure to
gain weight, lethargy, hyponatremia, hyperkalemia, and
acidosis) in the early period (2 weeks–1 month) were
evaluated as SW, and who were admitted with signs of
androgen excess (cliteromegaly, penile enlargement, rapid
growth, advancement in bone age, premature development
of pubic and/or axillary hair) at a later age (2–3 years) and
without salt loss were evaluated as SV [1–3].
The children’s legal guardian(s) provided written
informed consents. The study was conducted according
1

to the Declaration of Helsinki, and the study protocol was
approved by the local ethics committee.
2.2. Methods
Demographic and clinical data including chronological age
(CA), sex, type of CAH, doses of hydrocortisone (mg/m2/
day) and fludrocortisone (mg/m2/day), weight standard
deviation score (SDS), height, height SDS, body mass index
(BMI) SDS, height velocity (HV), height velocity SDS,
blood pressure (BP), and pubertal status (as prepubertal or
pubertal) were collected. Measurement of height, weight,
blood pressure, and bone age (BA) evaluation are stated in
the following source [16]. The auxological evaluation was
done according to Turkish National Growth Charts [17].
Blood pressure SDS was calculated according to Child
Metrics1 [18]. Obesity was defined as a BMI at or above
the 95th percentile of children of the same age and sex.
After an overnight fast, serum total cholesterol
(TC), high-density lipoprotein (HDL)-C, low-density
lipoprotein (LDL)-C and triglycerides (TG), fasting blood
glucose (FBG), 17-OH progesterone and androstenedione
were taken between 08:00 and 09:00 from all CAH
patients. Androstenedione and 17-OH progesterone
measurements were performed with commercially
available radioimmunoassay kits.
The patients were divided into two groups according to
the degree of control of clinic and laboratory parameters
as a) “uncontrolled” [n= 22; with increased HV SDS (≥2
SDS), advanced bone age, serum 17-OH progesterone
<2.0 and ≥10.0 ng/mL or androstenedione <0.3 and ≥
3.0 ng/mL] or b) “controlled” [n= 12; with HV SDS < 2,
bone age (BA)/chronologic age (CA) ratio < 1.2, serum
17-OH progesterone between 2 and 10 ng/mL and
androstenedione between 0.3 and 3.0 ng/mL].
2.3. Imaging
Ultrasonographic examination of carotid artery was
performed using a B-mode ultrasound system with a highdefinition L12-5 linear wide band transducer (Philips
HDI 5000 System, Bothell, WA, USA). Both left and
right common carotid arteries (CCA) were scanned. The
longitudinal plane images of the CCA at 1–2 cm proximal
to the carotid bulb were obtained and digitally archived.
All ultrasound examinations were performed according
to a standardized protocol by the same radiologist (TO)
who was blinded to the clinical details of the participants.
Archived images were transferred to a workstation, and
intima-media thickness (IMT) values were automatically
measured using a computer software (Q-LAB, ATLPhilips, Bothell, WA, USA). The measurements were
performed retrospectively in a single-blind manner. The
mean left and right CCA measurements were obtained,
and the mean IMT values were recorded.
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A radiograph of the left hand was used to determine
BA using the Greulich-Pyle atlas. All bone ages were
estimated by the same endocrinologist (HT). BA/CA rates
greater than 1.2 were defined as advanced bone age.
3. Statistical analysis
Statistical analyses of the data were conducted using
SPSS 21.0 (SPSS 21.0 for Windows, IBM Corp., Armonk,
NY, USA). Distribution of data was evaluated with the
Kolmogorov–Smirnov test. For numerical comparisons
between the study groups, the data was compared using
Student’s t-test (for normally distributed data) and the
Mann–Whitney U test (for nonnormally distributed data).
Pearson’s chi-squared test was used for the comparison of
categorical variables. The Kruskal–Wallis test was used to
compare CIMT differences between more than two groups
[(controlled and uncontrolled CAH patients and healthy
control cases) (SW type, SV type, and healthy control)].
Spearman’s or Pearson’s correlation analysis was used to
investigate the association between two variables. Data are
expressed as mean ± standard deviation (SD) or median
(IQR). p < 0.05 was considered statistically significant.
4. Results
The clinical and laboratory characteristics of the children
and adolescents are summarized in Table 1. A total of 34
patients with CAH (mean age of 10.4 ± 3.9 years, 17 males,
16 prepubertal) and 31 healthy subjects (mean age of 10.8
± 3.6 years, 16 males, 11 prepubertal) were included in
the study. The SW type of CAH represented 64.7% (n=
22) of the studied patients, while the SV type represented
35.3% (n= 12). All patients were receiving glucocorticoid
substitution therapy with hydrocortisone; in addition, 22
were receiving fludrocortisone. None of the patients was
receiving any additional medication.
CAH patients had significantly lower height SDS
and significantly higher BMI SDS compared to healthy
subjects (p = 0.012, p < 0.001, respectively). No significant
difference was detected between CAH patients and healthy
subjects in terms of age, sex, puberty, weight SDS, systolic
blood pressure (SBP) SDS, diastolic blood pressure (DBP)
SDS, FBG, HDL, LDL, TC or TG (p > 0.05). None of the
children in the CAH and control groups had hypertension.
Eleven (32.3%) patients in the CAH group were obese.
Median age at diagnosis of CAH was 0.14 years (IQR,
2.8). Mean duration of the treatment was 8.5 ± 3.7 years.
While the median age of diagnosis of SW patients was
0.04 years (IQR, 0.15), the median age of diagnosis of SV
patients was 6.0 years (IQR, 4.9). Mean serum 17-OH
progesterone and androstenedione concentrations in the
CAH group were 13.58 ± 12.85 ng/mL and 2.88 ± 3.44 ng/
mL, respectively. Median (IQR) CIMT values of CAH and
control groups were 0.47 (0.05) mm and 0.47 (0.07) mm,
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respectively. There was no significant difference between
the CAH and control groups in terms of CIMT values (p =
0.692). When compared according to sex, males with CAH
had significantly higher BMI SDS than healthy males, and
females with CAH had significantly higher BMI SDS and
height SDS than healthy females (p < 0.05); however, there
was no difference in terms of CIMT values (p > 0.05)
(Table 1).
When we compared the clinical and laboratory
characteristics of CAH patients according to metabolic
control, no difference was found in terms of age, age
at diagnosis, sex, puberty, duration of treatment,
hydrocortisone dose, fludrocortisone dose, weight SDS,
height SDS, BMI SDS, SBP SDS, DBP SDS, FBG, HDL,
LDL, TC, TG, HV SDS, or BA/CA ratio (p > 0.05) (Table
2). When subgroup comparisons were done in terms of
CIMT values, there was no significant difference between
the controlled, uncontrolled, and healthy control groups
(p = 0.127, Table 2, Figure 1). In addition, there was no
significant differences between the SW type CAH, SV
type CAH, and healthy control groups in terms of CIMT
values, SBP SDS, and DBP SDS (p = 0.906, Figure 2, p =
0.411, p = 0.341, respectively).
There was no correlation between CIMT and age,
weight SDS, height SDS, BMI SDS, hydrocortisone dose,
fludrocortisone dose, SBP SDS, DBP SDS, FBG, HDL, LDL,
TC, TG, 17-OH progesterone, or AS levels (p > 0.05) (data
not shown). Blood pressure (SDB SDS, DBP SDS) was not
correlated with hydrocortisone dose, fludrocortisone dose,
and duration of treatment (data not shown).
5. Discussion
Carotid intima-media thickness is an imaging technique
used to predict subclinical atherosclerosis, which is an
early predictor of future cardiovascular disorders [12].
It has been reported that endothelial dysfunction was
associated with CIMT progression [19]. Carotid intimamedia thickness has been reported to be associated with
family history, ethnicity, advanced age, male sex, high body
fat, high blood pressure, presence of diabetes or glucose
intolerance, and high serum cholesterol and triglyceride
levels [20]. It has been reported that obesity, hypertension,
dyslipidemia, insulin resistance and hypercortisolism or
hyperandrogenism may cause vascular dysfunction in
patients with CAH, resulting in coronary artery disease
[21]. Conflicting data have been reported on the effects of
CAH on CIMT. Some studies on subclinical atherosclerosis
have reported that CIMT was increased in children and
adult patients with CAH [11,12,15,22–25]. Nonetheless,
Harrington et al. [19] compared patients with obesity and
CAH to healthy subjects in terms of CIMT and found no
difference between the groups. In another study, Kim et
al. [13] reported that CIMT values were similar between

Table 1. Clinical and laboratory characteristics of the study groups.
All cases

Male

Female

CAH group
(n=34)

Control group
(n=31)

p

CAH group
(n=17)

Control group
(n=16)

p

CAH group
(n=17)

Control group
(n=15)

p

Age (years)

10.4 ± 3.9

10.8 ± 3.6

0.603a

9.1 ± 3.4

10.1 ± 3.3

0.351a

11.7 ± 4.1

11.7 ± 3.8

0.974a

Age at diagnosis (years)

0.14 (2.8)

-

-

0.2 (2.7)

-

-

0.02 (5.80)

-

-

Duration of treatment (years)

8.5 ± 3.7

-

-

7.8 ± 3.4

-

-

9.1 ± 3.9

-

-

Sex (M/F)

17 / 17

16 / 15

0.897

-

-

-

-

-

-

Prepubertal/pubertal

16/ 18

11 / 20

11/8

7/9

7/10

4/11

Pubertal stage 2

6

7

3

3

3

4

Pubertal stage 3

3

4

1

2

2

2

Pubertal stage 4

2

3

1

2

1

1

Pubertal stage 5

7

6

3

2

4

4

Normal/overweight/obese (n)

15/8/11

28/1/2

<0.001

9/3/6

14/1/1

0.644

6/5/5

14/0/1

0.616c

Weight SDS

0.63 ± 1.20

0.21± 0.93

0.128

0.5 ± 1.4

0.2 ± 0.9

0.528

0.8 ± 1.0

0.2 ± 1.0

0.110a

Height SDS

–0.17 ± 1.42

0.63 ± 1.05

0.012a

0.2 ± 1.5

0.6 ± 0.9

0.391a

–0.6 ± 1.1

0.7 ± 1.2

0.004a

BMI SDS

1.21 ± 0.72

–0.34 ± 1.3

< 0.001

1.1 ± 0.8

–0.1 ± 1.0

0.001

1.3 ± 0.6

–0.1 ± 1.0

<0.001a

SBP (mmHg)

102 ± 12

104 ± 11

0.458a

106 ± 11

107 ± 14

0.871a

98 ± 13

102 ± 7

0.389a

SBP SDS

0.14 (1.8)

–0.42 (0.9)

0.204

0.50 (1.36)

–0.25 (0.75)

0.076

–0.13 ± 0.96

–0.12 ± 0.93

0.993a

DBP (mmHg)

63 ± 11

68 ± 8

0.101

67 ± 12

71 ± 11

0.376

60 ± 11

66 ± 5

0.148a

DBP SDS

0.32 ± 0.9

0.48 ± 0.6

0.495a

0.53 ± 0.84

0.41 ± 0.38

0.670a

0.15 ± 0.98

0.51 ± 0.75

0.291a

FBG (mg/dL)

84.6 ± 9.3

88.9 ± 9.0

0.086

84 (17.5)

89.5 (17)

0.024

83.7 (11)

88.0 (10)

0.041b

HDL (mg/dL)

57.2 ± 12.6

52.1 ± 9.6

0.112a

61.8 ± 12.4

54.9 ± 10.6

0.142a

56.1 ± 12.9

49.2 ± 8.1

0.586a

LDL (mg/dL)

93.0 (46.7)

94.5 (32.0)

0.788

104.5 ± 29.0

88.6 ± 26.1

0.153

95.5 ± 31.9

102.2 ± 31.0

0.130a

TC (mg/dL)

175.1 ± 33.1

161.5 ± 33.1

0.140

180.3 ± 33.1

157.3 ± 31.2

0.078

169.7 ± 33.2

165.6 ± 35.8

0.758a

75 (41.5)

79 (49.2)

0.563b

74 (37)

68 (36)

0.817b

83 (63)

102 (49)

0.853b

Hydrocortisone dose (mg/m /day)

12.8 ± 4.1

-

-

13.2 ± 3.7

-

-

12.4 ± 4.5

-

-

Fludrocortisone treatment (n)

22

-

-

12

-

-

10

-

-

Fludrocortisone (mg/day)
Fludrocortisone
(mg/m2/day)
CIMT (mm)

0.1 (0.0)

-

-

0.1 (0.0)

-

-

0.1 (0.0)

-

-

0.47 (0.07)

0.692

0.49 (0.08)

0.929

0.46 (0.04)

0.502b

2

0.157

c

c

a

a

b
a

a

b
a

0.09 (0.08)
0.47 (0.05)

0.227

c

c
a

a

b
a

b

a
a

0.10 (0.15)
b

0.48 (0.08)

0.388c

0.08 (0.05)
b

0.47 (0.03)

Student’s t-test, bMann–Whitney U test, cChi-squared test. The values are presented as mean ± SD or median (IQR).
BMI-SDS: body mass index standard deviation score of body mass index, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, HDL: High-density lipoprotein, LDL: Lowdensity lipoprotein, TC: total cholesterol, TG: triglyceride, FBG: Fasting blood glucose, CIMT: Carotid intima-media thickness.
a
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TG (mg/dL)

c
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Table 2. Comparisons of the clinical and laboratory characteristics of the controlled, uncontrolled, and healthy control groups.
Controlled
(n=12)

Uncontrolled
(n=22)

Control
group (n=31)

p

Age (years)

9.6 (9.7)

10.8 (4.7)

10.5 (6.3)

0.854a

Sex (M/F)

6/6

11 / 11

15/16

0.992b

Puberty (Prepubertal/pubertal)

7/6

9 / 12

11/20

0.330b

Normal/overweight/obese (n)

7/3/3

8/5/8

28/1/2

<0.001b

SW/SV

9/3

13 / 9

-

0.354b

HV SDS

–0.67 (1.58)

–0.35 (4.49 )

-

0.461c

BA/CA ratio

1.08 (0.15)

1.2 (0.30)

-

0.075c

Hydrocortisone dose (mg/m2/day)

12.5 ± 4.8

13.0 ± 3.7

-

0.759d

Fludrocortisone (mg/m2/day)

0.10 (0.14)

0.08 (0.04)

-

0.186c

BMI SDS

1.04 ± 0.6

1.31 ± 0.7

–0.34 ± 1.3

<0.001e

SBP SDS

0.36 (1.7)

0.0 (1.2)

–0.42 (0.9)

0.329a

DBP SDS

0.55 ± 1.0

0.20 ± 0.8

0.48 ± 0.6

0.533e

FBG (mg/dL)

83.5 (14.7)

84.5 (13.0)

84.5 (13.0)

0.763a

HDL (mg/dL)

56.6 ± 10.8

57.6 ± 9.1

52.1 ± 9.6

0.196e

LDL (mg/dL)

102.4 ± 32.9

98.7 ± 29.7

95.5 ± 28.8

0.576e

TC (mg/dL)

175.2 ± 33.5

174.9 ± 33.8

161.5 ± 33.1

0.140e

TG (mg/dL)

74.5 (34.8)

75.0 (49.8)

79.0 (49.2)

0,810a

17- OH progesterone (ng/mL)

2.2 (5.8)

17.0 (24.4)

-

<0.001c

Androstenedione ng/mL

0.3 (1.2)

1.6 (7.3)

-

0.012c

CIMT (mm)

0.45 (0.03)

0.47 (0.04)

0.47 (0.07)

0.127a

Kruskal–Wallis test, bChi-squares test, cMann–Whitney U test, dStudent’s t-test, eOne way ANOVA test. The values are presented as
mean ± SD or median (IQR). M: male, F: female, SW: salt wasting, SV: simple virilizing, HV SDS: Height velocity standard deviation
score SDS, BA: Bone age, CA: Chronological age, BMI-SDS: Standard deviation score of body mass index, SBP: Systolic blood
pressure, DBP: Diastolic blood pressure, FBG: Fasting blood glucose, HDL: High-density lipoprotein, LDL: Low-density lipoprotein,
TC: total cholesterol, TG: triglyceride, CIMT: Carotid intima-media thickness.
a

CAH and healthy subjects, but significantly higher in
obese subjects compared to nonobese subjects in both
the patient and control groups. In the same study, it has
been shown that CIMT values in male CAH cases were
significantly higher than in females. In subgroup analysis,
CIMT values have been reported to be similar in SW and
SV type CAH cases [12,13]. In the study by Metwalley et
al. [22], CIMT values have been found to be significantly
higher in uncontrolled CAH cases than in well-controlled
cases and in both male and female CAH cases compared to
healthy subjects. In the same study, it has been shown that
CIMT was related to age, duration of treatment, equivalent
of hydrocortisone dose, 17-hydroxyprogesterone, and
testosterone. In our study, CIMT values were similar
between CAH patients and healthy subjects. In addition,
CIMT values were found to be similar in subgroups
according to sex, CAH forms (SW and SV) and control
status (controlled/uncontrolled) compared to healthy
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subjects. In addition, in our study, no correlation was
found between CIMT and age, BMI, hydrocortisone dose,
17-hydroxyprogesterone or androstenedione, conflicting
with the findings of some studies [13,22]. However, these
findings do not suggest an increased risk of cardiovascular
disease in our CAH patients at the age when they were
evaluated. The reasons for the similarity in CIMT values
between CAH cases and healthy subjects in the current
study may be due to i) the low number of cases, ii) failure to
evaluate the familial characteristics of patients or healthy
subjects in terms of risk of cardiovascular disease, iii) lack
of time for vascular change to occur for CIMT increase to
be observed.
The prevalence of obesity, hypertension, dyslipidemia,
and insulin resistance have previously been reported to
be increased in CAH patients. In our study, the height
SDS was lower, and BMI SDS was higher in patients
with CAH compared to healthy subjects, consistent with
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Figure 1. Comparisons of CIMT values according to status of disease control.

Figure 2. Comparisons of CIMT values in terms of CAH types.

the literature [26,27]. In addition, in our study, 32.3%
of the CAH patients were obese. Similarly, increased
obesity rates (16.8%–25%) have previously been reported
[5,12,15]. Obesity in CAH patients has been associated
with glucocorticoid therapy, high androgen levels, leptin

resistance, and decreased lipolysis due to the reduction in
catecholamine secretion [21].
Increased vascular tone due to obesity, hyperinsulinemia,
and glucocorticoid treatment may cause hypertension in
CAH patients [6]. Hypertension is a major cardiovascular
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morbidity in children and adolescents with CAH [5]. In
our study, none of the children in the CAH group had
hypertension. Moreover, in our study, no difference was
found between the CAH patients and healthy subjects
in terms of SBP or DBP. Some studies have reported
normal resting blood pressure values [13,22,25,28]
and 24-h BP profile [29] in children and young adults
with CAH compared to healthy subjects, similar to our
results. On the other hand, in studies performing blood
pressure assessment by 24-h BP profile, Da Silva et al.
[30] reported day-time SBP increase (between 90 and 95
percentile range) in 5 of 11 cases with CAH. Völkl et al.
[31] reported significantly higher SBP SDSs than healthy
subjects in both day-time and night-time, and Roche et al.
[4] reported 58% systolic and 24% diastolic hypertension
in 38 SW type CAH cases. Interestingly, in CAH cases with
normal resting SBP and DBP, peak SBP and DBP values
and increases in SBP and DBP values have been found to
be significantly higher during exercise than resting or daily
routine activity [32]. Although BP profile is not affected
in daily routine activities, it seems that BP responses may
be impaired during exercise in CAH cases due to their
metabolic dysregulation. Finally, contradictory results
from different studies could be explained by the facts that
a) hypertension may have been missed due to the lack
of 24-h blood pressure monitoring in CAH patients b)
significant alterations in vascular structure may not yet
have developed, and c) impaired exercise performance,
which may be an early marker of cardiovascular disease in
CAH patients, was not evaluated.
Increased frequency of obesity, insulin resistance,
hydrocortisone treatment and high androgen exposure
is expected to deteriorate the lipid profiles of CAH cases.
However, contrary to this expectation, the lipid profiles
were similar to healthy controls in this study. Most studies
on children and adults have reported similar lipid profiles
in CAH cases and healthy control subjects, similar to our
study [11,12,24,33–35]. In their study on prepubertal CAH
cases, Botero et al. [36] reported that TC, LDL, and HDL
values were similar, but TG values were significantly higher
in CAH cases compared to healthy subjects. However, it
has been noted that prednisone, which increases the risk of
metabolic alteration more than hydrocortisone, was used
in treatment in this study. In addition, Zimmermann et
al. [37] reported higher small, dense LDL and lower HDL
in CAH cases. However, their study groups were quite
heterogeneous in terms of age (age range: 4–31), which
was one of the main limitations of the study. One study
suggested that dyslipidemia may take time to develop,
which could be the reason for the lack of changes in lipid
profile in children with CAH [21]. In contrast to this
hypothesis, Falhammar et al. [35] reported similar serum
TC, HDL, LDL, and TG levels between CAH patients aged
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<30 years and CAH patients aged >30 years. Furthermore,
in the same study, the HDL/LDL ratio, which is considered
to be protective against cardiovascular disease, has been
reported to be significantly higher in CAH patients >30
years of age. In conclusion, contrary to expectations,
the current study showed no evidence to support lipid
alteration in CAH, as in many other studies. However, the
low number of cases in both our study and the previous
studies may have prevented us from demonstrating the
differences in lipid profiles.
The main limitation of our study was that we could not
exclude the impact of blood pressure changes. Although
there was no difference between the groups in terms of
blood pressures, intermittent elevated blood pressure may
cause endothelial dysfunction in the congenital adrenal
hyperplasia group [32]. Therefore, it would be more
appropriate to perform 24-h blood pressure monitoring
in congenital adrenal hyperplasia patients. Another
limitation was the low number of subgroup cases. In
addition, 17-hydroxyprogesterone and androstenedione
levels, which are indirect indicators of increase in
androgens, were evaluated, but testosterone and DHEAS
levels could not be measured. Therefore, we could not
investigate whether androgen levels were correlated
with CIMT. The effect of genetic factors affecting CIMT
and cardiovascular disease risk was not considered in
this study, as well. The risk of cardiovascular disease is
associated with fat distribution. The risk of this disease is
determined by waist circumference regardless of obesity
and is more reliable than BMI [38]. We have not performed
waist circumference measurements. 17-OH progesterone
was not studied in the control group. These are other
limitations in this study. The last limitation of the current
study is that androstenedione and 17-OH progesterone
levels were studied with the radioimmunoassay method.
In recent studies, it has obviously been demonstrated
that liquid chromatography-tandem mass spectrometry
is more reliable in steroid hormones, precursors, and
metabolic parameters than the RIA method [39].
In conclusion, in the present study, the CIMT values
of CAH cases were found to be similar to those of healthy
subjects. In addition, CIMT levels were similar according
to sex, disease control status, and CAH type and were
not associated with any anthropometric or metabolic
parameters. Although these findings suggest that the risk
of cardiovascular disease is low in CAH patients during
childhood and adolescence, it should be kept in mind that
clinically significant endothelial dysfunction may not yet
have occurred due to early age.
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